The LANCE® Ultra Human PD-L1 Detection Kit is designed for detection and quantitation of human PD-L1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human PD-L1 Detection Kit is designed for detection and quantitation of human PD-L1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Programmed death ligand 1 (PDL-1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PDL-1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PDL-1, together with PDL-2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PDL-1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cellcycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PDL-1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Application |
Protein Analysis & Detection
|
---|---|
Assay Points |
500
|
Assay Target |
PD-L1
|
Assay Target Class |
Protein
|
Automation Compatible |
Yes
|
Brand |
LANCE Ultra
|
Detection Method |
TR-FRET
|
Shipping Conditions |
Shipped in Blue Ice
|
Therapeutic Area |
Oncology
|
Unit Size |
500 Assay Points
|
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.